Anti-IgE monoclonal antibody - Sixal

Drug Profile

Anti-IgE monoclonal antibody - Sixal

Latest Information Update: 15 Jul 2016

Price : $50

At a glance

  • Originator Sixal
  • Class Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypersensitivity

Most Recent Events

  • 15 Jul 2016 Preclinical development is ongoing in USA
  • 03 Mar 2014 Preclinical trials in Hypersensitivity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top